N. Matthew Ellinwood, DVM, PhD, trained in molecular biology, reproductive physiology, innate immunity, and veterinary medicine at Colorado State University. Matthew did his residency in veterinary medical genetics and a post-doctoral fellowship in comparative medicine at the University of Pennsylvania, followed by a gene therapy fellowship (University of Nantes). He is Professor Emeritus at Iowa State University, where he worked (2004-2020) on natural history and preclinical studies of the MPS I and IIIB dog models. He served (2020-2025) as Chief Scientific Officer with the National MPS Society, Inc., where he guided research toward clinical and public health progress, particularly newborn screening. Before becoming CSO he served on the Society’s Scientific Advisory Board (SAB, 2004-2020). He is an active SAB member of the International MPS Network. Currently he consultants on metabolic disease issues in public health and newborn screening with Connetics Consulting LLC. He has direct experience with preclinical studies of hematopoietic stem cell transplantation, intravenous enzyme therapy, intracisternal enzyme therapy, intraventricular enzyme therapy, systemic intravenous AAV gene therapy, and intraparenchymal CNS AAV based therapy. His work on preclinical models of genetic diseases includes: SCID; MPSs I, IIIA, IIIB, IIID, VI, and VII; ML II alpha/beta; congenital glaucoma; and retinitis pigmentosa.